BioNTech to expand trial programme for more anti-Omicron COVID-19 vaccine options - CNA

FRANKFURT: BioNTech has expanded an ongoing clinical trial programme to develop new vaccines and patterns of administration for better protection against the dominant Omicron coronavirus variant as it reported a profit boost from its first-generation shot. …

FRANKFURT: BioNTech has expanded an ongoing clinical trial programme to develop new vaccines and patterns of administration for better protection against the dominant Omicron coronavirus variant as i… [+2678 chars]

full article...